Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Debt to Assets Over TimeElevated
Percentile Rank71
3Y CAGR+3.8%
5Y CAGR+17.5%
Studio
Year-over-Year Change

Debt-to-assets ratio

3Y CAGR
+3.8%/yr
Annual compound
5Y CAGR
+17.5%/yr
Recent deceleration
Percentile
P71
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
2 yr
Consecutive declineElevated
PeriodValueYoY Change
20251.18-31.6%
20241.72-34.6%
20232.63+149.8%
20221.05+54.3%
20210.68+29.9%
20200.52+7101.1%
20190.01-
20180.00-100.0%
20170.00-66.2%
20160.01-